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Binding sitea b s t r a c t
Pharmacological targeting of glutamate-gated chloride channels (GluCls) is a potent anthelmintic strat-
egy, evidenced by macrocyclic lactones that eliminate numerous roundworm infections by activating
roundworm GluCls. Given the recent identiﬁcation of ﬂatworm GluCls and the urgent need for drugs
against schistosomiasis, ﬂatworm GluCls should be evaluated as potential anthelmintic targets. This
study sought to identify agonists or modulators of one such GluCl, SmGluCl-2 from the parasitic ﬂatworm
Schistosoma mansoni. The effects of nine glutamate-like compounds and three monoterpenoid ion chan-
nel modulators were measured by electrophysiology at SmGluCl-2 recombinantly expressed in Xenopus
laevis oocytes. For comparison with an established anthelmintic target, experiments were also performed
on the AVR-14B GluCl from the parasitic roundworm Haemonchus contortus. L-Glutamate was the most
potent agonist at both GluCls, but L-2-aminoadipate, D-glutamate and D-2-aminoadipate activated SmG-
luCl-2 (EC50 1.0 ± 0.1 mM, 2.4 ± 0.4 mM, 3.6 ± 0.7 mM, respectively) more potently than AVR-14B. Quis-
qualate activated only SmGluCl-2 whereas L-aspartate activated only AVR-14B GluCls. Regarding the
monoterpenoids, both GluCls were inhibited by propofol, thymol and menthol, SmGluCl-2 most potently
by thymol (IC50 484 ± 85 lM) and least potently by menthol (IC50 > 3 mM). Computational docking sug-
gested that agonist and inhibitor potency is attributable to particular interactions with extracellular or
membrane-spanning amino acid residues. These results reveal that ﬂatworm GluCls are pharmacologi-
cally susceptible to numerous agonists and modulators and indicate that changes to the glutamate
c-carboxyl or to the propofol 6-isopropyl group can alter the differential pharmacology at ﬂatworm
and roundworm GluCls. This should inform the development of more potent compounds and in turn lead
to novel anthelmintics.
 2014 The Authors. Published by Elsevier Ltd. on behalf of Australian Society for Parasitology Inc. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Flatworm parasites are responsible for an astounding disease
burden in the developing world. This is exempliﬁed by blood ﬂukesthat currently inﬂict schistosomiasis on hundreds of millions of
people (Gryseels et al., 2006; King, 2010). The disease can be
deadly but in most cases causes a prolonged morbidity (van der
Werf et al., 2003; King et al., 2005) that is clearly associated with
oppressive poverty in the affected societies (King, 2010). Treat-
ment of schistosomiasis relies largely on the drug praziquantel,
which has been very successful (Doenhoff et al., 2008). A refractory
period in juvenile ﬂukes (Pica-Mattoccia and Cioli, 2004; Botros
et al., 2005), however, likely renders praziquantel ineffective in
areas of high transmission (Gryseels et al., 2001; Doenhoff et al.,
2008), and perhaps more alarmingly, very few drugs are available
as alternative treatments (Thetiot-Laurent et al., 2013). There is
thus a great need for new anthelmintics for schistosomiasis
(Caffrey and Secor, 2011; Thetiot-Laurent et al., 2013).
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glutamate-gated chloride channel (GluCl) of roundworms, a mem-
brane-bound receptor-channel in neuronal and muscle cells, where
it mediates an inhibitory chloride current in response to neuro-
transmitter binding (Wolstenholme, 2012). It is a uniquely inverte-
brate member of the pentameric ligand-gated ion channel (pLGIC)
family, also known as Cys-loop receptors. GluCls are closely related
to mammalian glycine receptor (GlyR) and Type A GABA receptor
(GABAAR) pLGICs (Dent, 2006). The potency of the GluCl as an
anthelmintic target is demonstrated by the widely used macrocy-
clic lactone, ivermectin, which binds with high afﬁnity to the mem-
brane-spanning domain of roundworm GluCls, irreversibly
activating a chloride current (Dent et al., 2000; Lynagh and
Lynch, 2012b). In the parasitic nematode, this depresses motor,
sensory and secretory systems (Kass et al., 1980; Perry, 2001;
Moreno et al., 2010), which serves to eliminate nematode infec-
tions frommillions of humans suffering from diseases such as river
blindness and lymphatic ﬁlariasis (Omura, 2008).
Despite their successful treatment of numerous roundworm
infections, macrocyclic lactones are largely ineffective against ﬂat-
worms, with practically no activity in ﬂukes (Shoop et al., 1995)
and relatively low potency at tapeworms (Campbell et al., 1983;
Perez-Serrano et al., 2001). Consequently, ﬂatworm GluCls did
not appear relevant as anthelmintic targets. Indeed, it was unclear
if GluCls were even present in ﬂatworms until very recently, when
four GluCl subunits, SmGluCl1-4, were isolated from Schistosoma
mansoni (Dufour et al., 2013). SmGluCl-2 and -3 form homomeric
channels that are not activated by macrocyclic lactones, but their
robust responses to L-glutamate, together with the conservation
of similar transcripts in other ﬂatworms (Dufour et al., 2013), sug-
gest that their pharmacological modulation could constitute a
novel treatment for a wide range of ﬂatworm parasites. Further-
more, these channels reveal similarities with roundworm GluCls,
suggesting that it may be possible for certain compounds to target
both roundworm and ﬂatworm GluCls, potentially leading to
anthelmintics of an unprecedented broad spectrum. A recent
high-resolution structure of a homomeric roundworm GluCl from
Caenorhabditis elegans has outlined general pLGIC architecture
and precisely deﬁned the binding sites for glutamate and ivermec-
tin (Hibbs and Gouaux, 2011). Glutamate binds in the extracellular
domain (ECD), between principal Loops A, B and C of one subunit
and complementary Loops D, E, F and G of an adjacent subunit.
Ivermectin occupies a cavity between adjacent subunits in the
transmembrane domain (TMD), which in mammalian pLGICs con-
tains binding sites for various modulators of agonist-induced
activation.
In the present work, a ﬂatworm GluCl was examined as a phar-
macological target in comparison to a roundworm GluCl that is
already established as a useful anthelmintic target. To this end,
the SmGluCl-2.1 from S. mansoni and the AVR-14B GluCl from
Haemonchus contortus were recombinantly expressed in Xenopus
laevis ooctyes, and both channels were tested for activation or
modulation by several compounds. These GluCls were selected
according to their qualities representative of other GluCls from
the respective phyla: SmGluCl-2.1 shows robust responses to glu-
tamate and is phylogenetically similar to numerous other ﬂat-
worm GluCls, both trematode and cestode (Dufour et al., 2013);
AVR-14B is highly conserved in parasitic roundworms (Beech
et al., 2010), has typical roundworm GluCl ivermectin sensitivity
(McCavera et al., 2009) and is a veriﬁed nematicidal target
(Glendinning et al., 2011). Compounds were selected due to their
analogy with known agonists that bind to the ECD or modulators
that bind to the TMD of other pLGICs. Several compounds acted
as moderate-to-low afﬁnity agonists or inhibitors, suggesting sitesfor potential anthelmintic compounds are possessed by ﬂatworm
and roundworm GluCls alike.2. Materials and methods
2.1. Drugs, chemicals, reagents
S. mansoni SmGluCl-2.1 (hereafter referred to as SmGluCl-2;
(Dufour et al., 2013); in the pT7TS vector) and H. contortus AVR-14B
(in pT7TS) cDNAs were kind donations from Professor Timothy
Geary (Institute of Parasitology, McGill University, Montréal,
Canada) and Professor Adrian Wolstenholme (Department of
Infectious Diseases, University of Georgia, Athens, GA, USA), respec-
tively. The AVR-14B Arg95Ala mutant cDNA was constructed using
mutagenesis primers synthesized by Euroﬁns MWG Operon
(Ebersberg, Germany) and the Quikchange II XL Site-Directed
Mutagenesis kit (Agilent Technologies, Böblingen, Germany), and
it was conﬁrmed by DNA sequencing (Euroﬁns MWG Operon). XbaI
was purchased from Fisher Scientiﬁc Germany GmbH (Schwerte,
Germany). The mMESSAGE mMACHINE T7 Kit for transcription
was purchased from Life Technologies GmbH (Darmstadt,
Germany). Chemicals and drugs were purchased from AppliChem
GmbH (Darmstadt, Germany), Carl Roth GmbH (Karlsruhe,
Germany), Sigma–Aldrich (Munich, Germany) or Tocris Bioscience
(R&D Systems GmbH, Wiesbaden-Nordenstadt, Germany).
2.2. Electrophysiological experiments
X. laevis oocytes were obtained, defolliculated and stored as pre-
viously described (Lynagh et al., 2013). After cDNA linearization
with XbaI and cRNA synthesis with the mMESSAGE mMACHINE
T7 kit, 4 ng cRNA was injected into defolliculated oocytes, and
oocytes were stored in frog Ringer’s solution (96 mM NaCl, 2 mM
KCl, 1 mM CaCl2, 1 mM MgCl2, 5 mM HEPES; pH 7.4 with NaOH;
50 lg/mL gentamycin). 2–5 days later, oocytes were transferred to
a recording chamber and constantly perfused with bath solution
(115 mMNaCl, 1 mMKCl, 1.8 mMCaCl2, 10 mMHEPES; pH7.4with
NaOH). Oocytes were two electrode voltage-clamped at 70 mV
with micropipettes ﬁlled with 3 M KCl. Currents were ﬁltered at
200 Hz and sampled at 1000 Hz with a Geneclamp 500B ampliﬁer,
Digidata 1322A interface and Clampex software (MolecularDevices,
Sunnyvale, CA, USA). Currents were measured in response to
increasing concentrations of L-glutamate or other agonists, each
dissolved in bath solution. Modulation of L-glutamate-induced
currents was tested by co-applying increasing concentrations of
the compound in question with the half maximal effective concen-
tration (EC50) of L-glutamate.
2.3. Amino acid sequence alignments, homology modeling and
dockings
Amino acid alignments were performed with ClustalX2 (Larkin
et al., 2007). To estimate the binding sites for the compounds
tested, comparative models of SmGluCl-2 and AVR-14B were built
on the template crystal structure of the C. elegans GLC-1 GluCl (PDB
entry 3RIF; (Hibbs and Gouaux, 2011)) using Modeller (Eswar et al.,
2006). Computational docking was performed with AutoDock Vina
including ﬂexible side chains (Trott and Olson, 2010). Glutamate
and related compounds were docked to each model within a cube
of sides 20 Å encompassing the L-glutamate binding site identiﬁed
in the C. elegans GLC-1 GluCl (Hibbs and Gouaux, 2011). Modula-
tors were docked to a 28  28  25 Å volume in the extracellular
half of the TMD, including intrasubunit cavities of two adjacent
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traversing from the membrane to the channel pore between two
M2 helices. Initial docking at this second site was performed with
ﬁxed side chains and then repeated with ﬂexible side chains
surrounding the preferred intersubunit site.2.4. Data analysis and statistical procedures
All data were analyzed in Prism4 software (GraphPad Software
Inc., San Diego, CA, USA). For calculation of EC50 and nH values, cur-
rent responses to agonists were plotted against log agonist concen-
tration and ﬁt with non-linear regression. Mean ± s.e.m. from at
least 3 individual experiments are reported. Maximal agonist-
induced currents (Imax) in tables and ﬁgures were normalized to
the mean maximal L-glutamate-induced current, which is itself
reported in the table. For the agonist dose–response curves in the
ﬁgures, data points are the mean ± s.e.m. for the indicated number
of experiments, and the curves are an illustrative ﬁt to these points.
For modulation of EC50 L-glutamate-induced currents, peak current
(cyan dashed lines in Fig. 5A and B) in the combined presence of
modulator and EC50 L-glutamate, as a percentage of peak current
in the presence of EC50 L-glutamate alone, was plotted against log
concentration of modulator. IC50 and nH values were also calcu-
lated with non-linear regression, and points and curves in ﬁgures
were generated as for agonists. In quantitating desensitization,
time taken for current to halve (t1/2) was calculated for maximal
and half-maximal L-glutamate-induced currents. Mean ± s.e.m. t1/2
values were compared with paired (maximal vs. half-maximal
for each channel) or unpaired (SmGluCl-2 vs. AVR-14B channels)
t tests (Prism4).Fig. 1. Compounds tested for effects at GluCls. (A) Compounds tested for agonist
effects. L- and D-isomers of glutamate and 2-aminoadipate were tested. (B)
Compounds tested for modulatory effects.3. Results
3.1. Glutamate-like compounds activate S. mansoni SmGluCl-2 and H.
contortus AVR-14B GluCls
In testing compounds for activity at SmGluCl-2 and AVR-14B
GluCls, we ﬁrst considered several compounds with structural
analogy to L-glutamate (Fig. 1), reasoning that these might also
act as agonists. To this end, L-glutamate, D-glutamate, L-2-aminoad-
ipate, D-2-aminoadipate, quisqualate, L-aspartate, cis-1-aminocyc-
lobutane-1,3-dicarboxylate (cis-ACBD), GABA, and glycine were
all applied at increasing concentrations to X. laevis oocytes injected
with SmGluCl-2 or AVR-14B cRNA and current responses were
recorded with two-electrode voltage clamp electrophysiology.
In SmGluCl-2-expressing oocytes, currents were activated
dose-dependently by L-glutamate, D-glutamate, L-2-aminoadipate,
D-2-aminoadipate and quisqualate (Fig. 2A and D). Currents
decreased in the continued presence of each agonist (Fig. 2A),
indicating that desensitization is a common feature of agonist
activity at SmGluCl-2. L-glutamate was by far the most potent
agonist, with an EC50 value of 24 ± 3 lM, 1.5 orders of magnitude
lower than that of the next-most potent agonist (Table 1) and
similar to that previously reported for SmGluCl-2 (Dufour et al.,
2013). The time taken for EC50 and saturating L-glutamate-
induced currents to decay to half-maximal amplitude was
9.3 ± 1.1 s and 5.3 ± 0.8 s, respectively (n = 4). These values are
signiﬁcantly different (P < 0.01; paired t test), indicating that
desensitization is faster at higher agonist concentrations.
L-2-aminoadipate and D-glutamate were both full agonists at
SmGluCl-2, with EC50 values of 1.0 ± 0.1 mM and 2.4 ± 0.4 mM
and maximal currents (Imax values) that equated to 93 ± 6% and
100 ± 6% that activated by L-glutamate, respectively (absolute Imax
values were not signiﬁcantly different from L-glutamate when
analyzed with paired t-test). D-2-aminoadipate, with an EC50 of3.6 ± 0.7 mM, activated currents with an Imax of 86 ± 3% that of
L-glutamate, indicating that the D-isomer is a partial agonist at
the SmGluCl-2 (absolute Imax values were signiﬁcantly less than
L-glutamate at individual oocytes, n = 4, P < 0.05, paired t-test).
Quisqualate, which differs from the other L-glutamate analogues
in the presence of a 1,2,4-oxadiazolidine-3,5-dione instead of a
carboxyl terminal (Fig. 1), at the highest concentration tested
(10 mM) activated currents equivalent to 28 ± 5% the L-glutamate
Imax (Fig. 2A). No currents were activated by L-aspartate, GABA,
glycine (each at concentrations up to 100 mM) or cis-ACBD
(at concentrations up to 10 mM). Numerous compounds bind to
but do not activate pLGICs, thus acting as competitive antagonists
of channel activation. We tested this possibility for L-aspartate,
GABA, glycine and cis-ACBD at the SmGluCl-2 by co-applying these
compounds at 100 mM (or 10 mM for cis-ACBD) with submaximal
concentrations of L-glutamate. No antagonism of current responses
to L-glutamate was observed for any of the compounds (data not
shown), indicating that the absence of agonist effects is indeed
due to low binding afﬁnity.
We next examined the agonist effects of these compounds at
the H. contortus AVR-14B GluCl, in order to establish if similar sites
for these compounds are conserved in roundworm and ﬂatworm
GluCls. Like the SmGluCl-2, the AVR-14B GluCl was activated by
several of the tested compounds, with each agonist causing signif-
icant desensitization (Fig. 2B). Again, L-glutamate was the most
potent agonist, with an EC50 of 21 ± 6 lM, similar to previous
Fig. 2. Agonist effects of L-glutamate-like compounds. (A–C) Typical current responses to selected compounds at oocytes expressing wild-type SmGluCl-2 (A), wild-type AVR-
14B (B), or mutant Arg95Ala AVR-14B. L-Glu, L-glutamate; L-Asp, L-aspartate; L-AA, L-aminoadipate; Quisq, quisqualate. (D,E) Current amplitude normalized to maximum
L-glutamate-induced current (% IL-Glutamate; mean ± s.e.m. n = 3–5) in response to increasing concentrations of all compounds at wild-type SmGluCl-2 (D) and AVR-14B (E).
Mean data points are ﬁt with non-linear regression for display. Fits for individual experiments were used to calculate the parameters in Table 1.
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urating L-glutamate-induced currents to decay to half-maximal
amplitude was 3.4 ± 0.6 s and 2.8 ± 0.7 s, respectively (n = 4). These
values are not signiﬁcantly different from each other (paired t test)
and both signiﬁcantly lower than the corresponding values at
SmGluCl-2 (P < 0.01 for EC50 and P < 0.05 for saturating; unpaired
t test). This indicates that desensitization of AVR-14B channels is
(1) similar at low and high agonist concentrations and (2) faster
than SmGluCl-2 channels.
L-2-aminoadipate also acted as a full agonist (Fig. 2B and E) with
an EC50 that was two orders of magnitude higher than L-glutamate
(Table 1). D-isomers of glutamate and 2-aminoadipate were mark-
edly less potent at the AVR-14B GluCl than at the SmGluCl-2 (com-
pare ﬁlled circles in Fig. 2D to ﬁlled circles in Fig. 2E), activating
currents that equated to only 67 ± 5% and 3 ± 1%, respectively, ofTable 1
Agonist parameters of L-glutamate analogues at SmGluCl-2 and AVR-14B GluCls.
SmGluCl-2
EC50 (mM) nH Imax (lA or %a)
L-glutamate 0.024 ± 0.003 1.8 ± 0.2 3.2 ± 0.6
D-glutamate 2.4 ± 0.4 1.1 ± 0.1 100 ± 6
L-2-aminoadipate 1.0 ± 0.1 1.7 ± 0.3 93 ± 6
D-2-aminoadipate 3.6 ± 0.7 1.0 ± 0.1 86 ± 3
L-aspartate
b b 1 ± 1
Quisqualate c c 28 ± 5
cis-ACBD b b 0
GABA b b 0
Glycine b b 0
a Absolute L-glutamate Imax reported in lA; all others as percentage of L-glutamate Im
b Inactive.
c Current activated by 10 mM quisqualate.the L-glutamate Imax at the AVR-14B GluCl. The EC50 of D-glutamate
was 8.8 ± 0.6 mM, more than two orders of magnitude greater than
that of L-glutamate. Also in contrast to SmGluCl-2, the AVR-14B
GluCl was not activated by 10 mM quisqualate but was robustly
activated by L-aspartate as a partial agonist (compare Fig. 2A and
B), with an Imax of 17 ± 7% that of L-glutamate and an EC50 of
8.7 ± 3 mM (n = 3). 100 mM GABA, 100 mM glycine and 10 mM
cis-ACBD activated no current and did not inhibit responses to
EC50 L-glutamate at the AVR-14B GluCl (data not shown).
Finally, we sought to exclude the possibility that the observed
responses to high agonist concentrations were not GluCl-mediated
and were mediated by some endogenous oocyte channel. To this
end, we tested the effects of agonists at 100 mM on oocytes
injected with mutated, Arg95Ala AVR-14B cRNA. This arginine
putatively contributes to L-glutamate binding (position 7 inAVR-14B GluCl
n EC50 (mM) nH Imax (lA or %a) n
7 0.021 ± 0.006 1.9 ± 0.2 3.1 ± 0.3 4
3 8.8 ± 0.6 2.3 ± 0.1 67 ± 5 4
4 2.6 ± 1.0 1.3 ± 0.2 98 ± 2 6
4 b b 4 ± 1 3
3 8.7 ± 0.3 1.5 ± 0.4 17 ± 7 3
3 b b 0 3
4 b b 0 4
3 b b 0 3
3 b b 0 3
ax.
Fig. 3. Simulated dockings to extracellular L-glutamate-binding domain. (A) GLC-1 crystal structure (Protein Database entry 3RIF), viewed from within the membrane plane.
Two adjacent subunits are shown in cyan and magenta. (B) Detailed view of boxed area in (A), showing bound L-glutamate molecule and proximal side chains: 1, Pro93 and 2,
Phe91 in Loop A; 3, Tyr151 in Loop B; 4, Tyr200 and 5, Thr197 in Loop C; 6, Arg37 in Loop G; 7, Arg56 in Loop D; and 8, Ser121 in Loop E (Hibbs and Gouaux, 2011). Part of Loop
C in the foreground is removed for clarity. (C–J) dockings of L-glutamate (C and D), L-aminoadipate (EC and F), L-aspartate (GC and H) and quisqualate (IC and J) to homology
models of SmGluCl-2 (C, E, G, I) or AVR-14B (D, F, H, J). Dashed lines indicate distances 63.2 Å. Side chains equivalent to those in GLC-1 are numbered as in (B), including an
additional serine, 9, in SmGluCl-2 Loop C (C, E, G, I). (K) Relevant segments from an amino acid alignment of Caenorhabditis elegans GLC-1, Schistosoma mansoni SmGluCl-2 and
Haemonchus contortus AVR-14B, indicating the equivalence of the illustrated side chains.
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Fig. 4. Propofol inhibition of SmGluCl-2. (A) Typical current responses to EC50
L-glutamate in the presence of increasing concentrations of propofol at an oocyte
expressing SmGluCl-2. (B) Current responses at SmGluCl-2-expressing oocytes
(black circles) to EC50 L-glutamate in the presence of propofol at increasing
concentrations, normalized to the response in the absence of propofol (% IL-Glutamate;
mean ± s.e.m. n = 5). Mean data points are ﬁt with non-linear regression for display.
Fits for individual experiments were used to calculate the parameters in Table 2.
Dashed line/grey circles illustrate the same experiments at AVR-14B-expressing
oocytes, from (Lynagh and Laube, 2014).
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nist-gated currents without affecting functional expression; if
oocytes injected with Arg95Ala cRNA showed no response to
100 mM agonist concentrations, this would rule out the contribu-
tion of other endogenous channels to current responses. Despite
robust Arg95Ala GluCl expression, as evident in ivermectin-
activated currents, these oocytes did not respond to 100 mM
agonist concentrations (Fig. 2C), conﬁrming that the responses of
wild-type cRNA-injected oocytes were indeed mediated directly
by GluCls.
3.2. Computational docking to homology model ECDs
L-glutamate binds to GluCls in the ECD at the interface of adja-
cent subunits (Fig. 3A and B), as illustrated by the crystal structure
of the C. elegans GLC-1 GluCl in complex with L-glutamate (Hibbs
and Gouaux, 2011). To investigate the molecular basis for the dif-
ferential pharmacology of GluCls, we ﬁrst built homology models
of SmGluCl-2 and AVR-14B GluCls on the C. elegans GLC-1 GluCl
template (PDB entry 3RIF). SmGluCl-2 and AVR-14B share
30–50% amino acid identity with GLC-1, enabling modeling with
a high degree of conﬁdence. Other than a proline/glutamine differ-
ence (position ‘‘1’’ in Fig. 3B) in Loop A, all of the key residues that
interact with the bound agonist in the 3RIF GLC-1 structure are
conserved in AVR-14B. These include two tyrosine residues
(positions 3 and 4 in Loops B and C, respectively, in Fig. 3B) in
the so-called aromatic box that coordinate the agonist primary
amine; threonine, arginine and serine residues (positions 5, 7,
and 8 in Loops C, D and E, respectively, in Fig. 3B) that coordinate
the agonist c-carboxyl; and a loop G arginine that coordinates the
agonist a-carboxyl in GLC-1 (position 6 in Fig. 3B). There are
however some notable differences between SmGluCl-2 and both
AVR-14B and GLC-1. Firstly there are two extra residues between
the two disulphide-linked cysteines in loop C, as shown in
Fig. 3K. In an SmGluCl-2 model built on this alignment, the
residues surrounding the agonist, described above, are largely
conserved, except for an arginine in place of the Loop A proline/
glutamine; an uncharged leucine in place of the loop G arginine
that coordinates the agonist c-carboxyl in GLC-1; and an extra
tyrosine from loop C contributing to the aromatic box (Fig. 3K).
To identify potential determinants of differential pharmacology,
the ligands tested above were computationally docked to SmGluCl-
2 and AVR-14B homology models. The highest ranked docking of
L-glutamate to AVR-14B adopted a position similar to that in the
C. elegans GLC-1 crystal structure, with the agonist amino nitrogen
in close proximity to the two aromatic box tyrosines from Loops B
and C of the principal face (Fig. 3B and D) and forming an H-bond to
the loop-B backbone (not shown). The L-glutamate c-carboxyl
formed a salt-bridge with the Loop D arginine of the AVR-14B com-
plementary face and similar H-bondswith the Loop C threonine and
loop E serine side chains (Fig. 3D). Likewise, the L-glutamate
a-carboxyl formed a salt-bridge with the Loop G arginine at the
‘‘bottom’’ of the AVR-14B site, similar to that in the GLC-1 structure.
Conversely, when docked to SmGluCl-2, the L-glutamate a-carboxyl
formed a salt-bridge with loop A arginine side chain, in the absence
of a Loop G arginine (Fig. 3C). The altered position of this coordinat-
ing charge, from the ‘‘bottom’’ (Fig. 3D) in AVR-14B to the ‘‘left’’
(‘‘Fig. 3C) of the agonist site in SmGluCl-2, may be a signiﬁcant fac-
tor in changes to other agonist-receptor interactions. The docked
primary amine shifts more to the ‘‘right’’ in SmGluCl-2, removing
the H-bond to the loop B backbone and shifting the most apparent
cation-p bond from a Loop C tyrosine to a loop B tyrosine. Although
the L-glutamate c-carboxyl again formed a salt-bridge with the
Loop D arginine and an H-bond with the Loop C threonine, the
H-bond to the Loop E serine was replaced by one with a Loop C
serine. The additional tyrosine in SmGluCl-2 loop C, not presentin AVR-14B (Fig. 3K; omitted for clarity from other illustrations),
forms apparent hydrophobic interactions with b- and c-carbon
atoms of L-glutamate that may stabilize this orientation of bound
agonist.
Other ligands that activated both channels showed reasonably
similar binding modes to L-glutamate at each model, including
the full agonist L-2-aminoadipate (Fig. 3E and F) but with some
modiﬁcations to accommodate the longer agonist. In general,
D-isomers docked best in a ﬂipped orientation (not shown), such
that the agonist a-carboxyl interacts with the complementary face
Loop D arginine and the a-amino nitrogen can form a cation-p
interaction with the Loop B tyrosine even in the AVR-14B site.
Slightly lower-ranked docks of D-glutamate to SmGluCl-2 showed
similar receptor-agonist interactions to L-glutamate, apparently
better accommodating the altered stereochemistry of D-glutamate
than AVR-14B, perhaps underlying the lower L/D selectivity of
SmGluCl-2. In dockings of L-aspartate to both channels (Fig. 3G
and H), agonist carboxyl groups interacted with the same posi-
tively charged side chains but, relative to L-glutamate, the two car-
boxyl groups were effectively swapped, ﬂipping the agonist such
that the a-carboxyl was oriented towards the complementary face.
This arrangement alters many interactions, notably shifting major
cation-p interactions from the Loop C tyrosine to the Loop B
tyrosine in AVR-14B and away from any aromatic side chain in
SmGluCl-2, perhaps explaining the selective agonist activity of
L-aspartate at the AVR-14B GluCl. Dockings of quisqualate
appeared similar at both receptors, although an interaction
between the agonist oxodiazolidine-3,5-dione terminal and the
Loop C threonine side chain was lacking in the AVR-14B
(Fig. 3I,J), perhaps explaining its selective activity at the
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relating with their lack of activity at both channels.3.3. Monoterpenoids inhibit SmGluCl-2 and AVR-14B GluCls
It was recently shown that the AVR-14B GluCl contains a TMD
binding site for the general anesthetic propofol (2,6-diisopropyl-
phenol), which in the micromolar range inhibits responses to L-glu-
tamate (Lynagh and Laube, 2014). If propofol were to inhibit
ﬂatworm GluCls at low concentrations it could constitute a novel
anthelmintic lead, and therefore, the SmGluCl-2 was tested for sen-
sitivity to propofol. Responses to EC50 L-glutamate were dose-
dependently inhibited by propofol (Fig. 4), with an IC50 of
1.1 ± 0.4 mM (n = 5). This is higher than the concentrations of pro-
pofol required for inhibition of AVR-14B (Fig. 4B) and substantially
higher than the concentrations of propofol that enhance human
ion channels and induce anesthesia (Franks and Lieb, 1994). Propo-
fol itself is therefore unsuitable as an anthelmintic. However, givenFig. 5. Thymol and menthol inhibition of GluCls. (A and B) Typical current
responses to EC50 L-glutamate in the presence of increasing concentrations of
thymol at an oocyte expressing SmGluCl-2 (A) or AVR-14B (B). Cyan dashed line
indicates peak current responses; purple dashed line indicates current after 30 s
agonist application. Note in (B) that 3 mM thymol caused an increase in the current
after 30 s agonist application. (C) Peak current responses at SmGluCl-2- and AVR-
14B-expressing oocytes to EC50 L-glutamate in the presence of thymol or menthol
at increasing concentrations, normalized to response in the absence of modulator
(% IL-Glutamate; mean ± s.e.m. n = 3–4). Mean data points are ﬁt with non-linear
regression for display. Fits for individual experiments were used to calculate the
parameters in Table 2.that certain propofol derivatives can modulate pLGICs with >1000-
fold greater potency than propofol (de la Roche et al., 2012) and
that the structurally related monoterpenoids thymol (2-isopro-
pyl-5-methyl-phenol) and menthol (2-isopropyl-5-methyl-phenol)
modulate pLGICs (Priestley et al., 2003; Tong and Coats, 2012), we
considered that these might modulate the SmGluCl-2 with greater
potency than propofol.
Thymol dose-dependently inhibited up to 95 ± 4% (n = 4) of the
L-glutamate response at the SmGluCl-2 (Fig. 5A), with an IC50 value
of 484 ± 85 lM (n = 4) that is lower than, but not signiﬁcantly dif-
ferent from, that of propofol (Table 2). Thymol also inhibited the
AVR-14B GluCl (Fig. 5B), but with an IC50 value of 1.2 ± 0.2 mM
(n = 4), signiﬁcantly higher than that at the SmGluCl-2 (P < 0.05,
unpaired t-test), and to a smaller maximal extent than SmGluCl-
2 (P < 0.05, unpaired t-test). The results reported thus far refer to
inhibition of the peak current responses to EC50 L-glutamate (cyan
dashed lines in Fig. 5A and B). Fig. 5B shows that although thymol
inhibited peak currents at the AVR-14B GluCl, it actually enhanced
the current present after prolonged L-glutamate application (pur-
ple dashed lines in Fig. 5B). This effect did not show robust dose-
dependency and was not analyzed further. Taken together, these
data indicate that thymol is more potent than propofol in inhibit-
ing SmGluCl-2, whereas the converse is true for inhibition of the
AVR-14B GluCl. Finally, we tested for inhibition of both GluCls by
menthol. Menthol and thymol are identical compounds but for
the absence of double bonds in the cyclohexyl backbone of men-
thol (Fig. 1). Menthol inhibited both GluCls (Fig. 5C), with 10 mM
menthol (highest concentration tested) causing 83 ± 5% (n = 3)
and 49 ± 9% (n = 4) inhibition of EC50 L-glutamate responses at
Sm-GluCl-2 and AVR-14B GluCls, respectively. Menthol is thus
substantially less potent than propofol or thymol at inhibiting
either GluCl.
3.4. Computational docking of monoterpenoids to the TMD
With a view to establish the determinants of monoterpenoid
inhibition of GluCls, each compound was docked to the TMD of
SmGluCl-2 and AVR-14B homology models. Dockings were permit-
ted within a large volume that included both the space between
helices M1-M4 of a single subunit (‘‘intrasubunit cavity’’), equiva-
lent to the binding site for propofol in the crystal structure of the
bacterial pLGIC GLIC (Nury et al., 2011), and the space between
adjacent subunits (‘‘intersubunit cavity’’). All compounds docked
preferably to one of two sites within the intersubunit cavity
(Fig. 6A and B). Propofol docked preferably to Site 2 in the SmG-
luCl-2 model, close to the channel-lining M2 helices (Fig. 6C),
whereas it docked preferably to Site 1 in the AVR-14B model, fur-
ther from M2 helices and more directly between M3 and M1 heli-
ces from adjacent subunits (Fig. 6D). This difference may be due to
the M3 isoleucine side chain in SmGluCl-2 reducing access to Site 1
(orange side chain in Fig. 6C). None of the compounds docked
within the intrasubunit cavity, equivalent to the propofol site in
the GLIC/propofol crystal structure (Nury et al., 2011), as neither
SmGluCl-2 nor AVR-14B models showed a cavity here that was
large enough to accommodate any of the monoterpenoids.
Similar patterns were observed for thymol and menthol, with
both docking preferentially to Site 1 in the AVR-14B model. For
thymol docking to the SmGluCl-2, the ﬁve highest ranked dockings
yielded similar binding energies, and although the highest ranked
was to Site 1 (Fig. 6E), the other four were to Site 2. In fact, in both
models, docking poses of each compound were identiﬁed at each of
the two sites, with the exception of propofol at the AVR-14Bmodel,
which docked exclusively to Site 1. That is, most compounds
docked with similar predicted free energies (6–7 kcal/mol) to both
sites in both channels, but Site 1 was preferred in the AVR-14B
model and Site 2 was preferred in the SmGluCl-2 model, likely
Table 2
Parameters for GluCl inhibition by propofol, thymol and menthol.
SmGluCl-2 AVR-14B GluCl
IC50 nH Max. Inhibitiona (%) n IC50 nH Max. Inhibitiona (%) n
Propofol 1.1 ± 0.4 mM 2.1 ± 0.9 91 ± 2 5 252 ± 48 lM b 2.4 ± 0.5b 96 ± 1 4b
Thymol 484 ± 85 lM 1.6 ± 0.2 95 ± 4 4 1.2 ± 0.2 mM 2.3 ± 0.8 75 ± 5 4
Menthol c c 83 ± 5d 3 c c 49 ± 9d 4
a Maximum inhibition of EC50 L-glutamate-activated currents.
b From (Lynagh and Laube, 2014).
c Saturating effect not observed.
d Inhibition caused by 10 mM menthol, the highest concentration tested.
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Site 1. The dockings also followed the trend that for each com-
pound, the hydroxyl group was usually oriented towards the M1
helix speciﬁcally in the GluCl that was most potently inhibited
by that compound. This proximity of the ligand hydroxyl is consis-
tent with the formation of an H-bond with the backbone carbonyl
of an M1 residue (alanine in SmGluCl-2, isoleucine in AVR-14B),
made available due to the conserved M1 proline four residues
downstream (Hibbs and Gouaux, 2011).
4. Discussion
4.1. Agonists in the GluCl ECD
The ﬂatworm SmGluCl-2 and the roundworm AVR-14B share
some expected similarities. From the compounds examined, both
channels are most potently activated by L-glutamate. This accords
with our homology models, showing at the appropriate positions
in both receptors the functional side chains that directly interact
with bound L-glutamate in the GLC-1 GluCl crystal structure
(Hibbs and Gouaux, 2011). There is one key exception, as the Loop
G arginine that interacts with the L-glutamate a-carboxyl in AVR-
14B is absent from SmGluCl-2, where its functional role is appar-
ently taken over by a Loop A arginine. Amino acid sequence align-
ments of S. mansoni GluCls (Dufour et al., 2013) and also of other
trematode transcripts (not shown) suggest that the Loop A arginine
is a molecular characteristic of ﬂatworm GluCls. D-glutamate also
acts as a full agonist or strong partial agonist at both channels, with
100- and 400-fold lower apparent afﬁnity than L-glutamate at
SmGluCl-2 and AVR-14B, respectively. This difference in potencies
of L- and D-isomers is quite similar to that seen at tetrameric gluta-
mate-gated cation channels (ionotropic glutamate receptors,
iGluRs; (Traynelis et al., 2010)). The full agonism and low millimo-
lar EC50 values of L-2-aminoadipic acid at both receptors reﬂects the
similarity in the agonist site of the two GluCls. It is perhaps surpris-
ing that this longer compound activates currents as large as those
activated by L-glutamate, in contrast to iGluRs, where it is much less
efﬁcacious than L-glutamate (Fay et al., 2009). Interestingly, the
higher selectivity of AVR-14B for L- over D-glutamate, relative to
SmGluCl-2, is continued with an even greater difference for L- over
D-2-aminoadipate. Consequently, D-2-aminoadipate is effectively a
selective agonist for SmGluCl-2 over AVR-14B GluCls.
The rank order of potency at the AVR-14B of L-glutamate > L-2-
aminoadipate > D-glutamate > L-aspartate concurs quite well with
the potency of these compounds in inhibiting [3H]L-glutamate
binding to the C. elegans GLC-1 (Hibbs and Gouaux, 2011), consis-
tent with closely related agonist-binding sites (Fig. 3) in these
closely related roundworm GluCls (Beech et al., 2010). Ibotenate
(not tested here due to availability) is also a partial agonist at the
AVR-14B GluCl, although more potent than the compounds tested
here, with an Imax equivalent to 69% that of L-glutamate and an
EC50 only 3-fold higher than L-glutamate (McCavera et al., 2009).
Ibotenate contains a-amino and -carboxyl groups, but less likeglutamate and more like quisqualate, possesses at the opposite ter-
minal a non-carboxyl, 3-oxyisoxazol group. This indicates that an
additional carboxyl group is not an absolute requirement for ago-
nist activity at the AVR-14B GluCl.
In contrast to the AVR-14B GluCl, the SmGluCl-2 was activated
up to 28% of the L-glutamate Imax by 10 mM quisqualate, the high-
est molecular weight compound tested. Thus, certain compounds –
L-glutamate and L-2-aminoadipate – share the same effects at both
GluCls, whereas others – L-aspartate, D-2-aminoadipate, quisqua-
late and to some extent D-glutamate – are selective for one GluCl
or the other. Fig. 3 shows that the architecture of the agonist bind-
ing site is quite similar between the two GluCls. Nevertheless, dif-
ferences such as a longer Loop C and the different position of the
positively charged arginine that coordinates the agonist a-carboxyl
in the SmGluCl-2 (Fig. 3K) may contribute to differences in agonist
speciﬁcity. Taken together, these data indicate that agonist phar-
macophores in both channels include a-amino and a-carboxyl
groups at one terminal of the ligand and carboxyl or other oxy-
gen-containing groups at the opposite terminal of the ligand.
Therefore, we speculate that testing further glutamate analogues
with alterations to the c-carboxyl group could reveal numerous
agonists of parasite GluCls. Even with the small number of com-
pounds tested here, it is clear that various drugs could selectively
activate ﬂatworm or roundworm GluCls, whereas others could
activate both and therefore target a broader spectrum of parasites.
Three observations lead us to believe that the L-glutamate bind-
ing site in invertebrate GluCls holds promise as an anthelmintic
target. Firstly, roundworms and ﬂatworms both possess GluCls at
which agonist binding induces robust channel activation. That
GluCl channel activation constitutes an effective and a safe anthel-
mintic mechanism is already established for roundworms
(Wolstenholme and Rogers, 2005; Omura, 2008). Although this
awaits testing in ﬂatworms, the GluCls of the ﬂuke S. mansoni are
functionally similar to their roundworm counterparts ((Dufour
et al., 2013); present study), and there is evidence for glutamater-
gic transmission in both tapeworms and ﬂukes (Webb and Eklove,
1989; Webb, 1995b; Brownlee and Fairweather, 1996), admittedly
also due to an excitatory, iGluR system (Mendonca-Silva et al.,
2002; Taman and Ribeiro, 2011). A notable example of gluta-
mate-like compounds eliciting anthelmintic effects is a decreased
tapeworm burden in rats upon a dose of monosodium glutamate
(Webb, 1995a), although the means by which this occurs is
unknown. Secondly, the structural/chemical landscape of the L-glu-
tamate binding site differs greatly between helminth GluCls on one
hand and mammalian receptors for L-glutamate, such as iGluRs
and glutamate transporters, on the other. Hibbs and Gouaux
(Hibbs and Gouaux, 2011) showed with a C. elegans GluCl crystal
structure that the a-amino, the a-carboxyl and the c-carboxyl
groups of L-glutamate are distinctly recognized by, respectively:
an aromatic box; a positively charged arginine side chain; and a
positively charged arginine side chain together with vicinal hydro-
xyl side chains. Our models suggest a similar site in other round-
worm and ﬂatworm GluCls. By contrast, in mammalian iGluRs,
Fig. 6. Simulated dockings to transmembrane domain. (A) Two adjacent subunits of SmGluCl-2 model, viewed from within the membrane plane. Green/blue spheres indicate
the vertical level of the sites. (B) Sites 1 (green) and 2 (blue) of the intersubunit cavity are illustrated with spheres. Only the transmembrane helices M1-M4 of adjacent
subunits are shown from above. (C-H) Detailed view of inter-subunit cavity in Sm-GluCl-2 (C, E, G) and AVR-14B (D, F, H), showing highest energy dockings of propofol (C and
D), thymol (E and F) and menthol (G and H). Color of compound indicates its position in Site 1 or Site 2. Several proximal side chains are indicated and labeled 1–8 in (H) and
(I); the alignment of these positions in SmGluCl-2 and AVR-14B subunits is shown in (I). (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
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by, respectively: a negatively charged glutamate or aspartate side
chain; a positively charged arginine side chain; and a pair of hydro-
xyl serine/threonine side chains (Mayer, 2006; Traynelis et al.,
2010). Likewise, the make-up of the L-glutamate binding site inmammalian metabotropic glutamate receptors (Kunishima et al.,
2000) and glutamate transporters (Yernool et al., 2004) is also very
different from that in the GluCl. This implies that helminth GluCls
and mammalian L-glutamate receptors likely possess different
susceptibility to various other compounds. Thirdly, a handful of
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or disable the parasite via activation of invertebrate acetylcholine
receptors (nAChRs; (Harrow and Gration, 1985; Millar and
Denholm, 2007)). Given the important role of nAChRs in the
human nervous system (Millar and Gotti, 2009) and the relatively
subtle differences between invertebrate and mammalian nAChRs
(Matsuda et al., 2005), it is remarkable that effective pesticides
target the agonist site of invertebrate nAChRs. There are greater
differences between invertebrate GluCls and their closest
mammalian relatives, GlyRs and GABAARs, particularly at the
agonist-binding site. Thus, we envisage good prospects for devel-
oping GluCl agonists with great selectivity for invertebrate over
mammalian receptors.
Finally, we note that both parasite GluCls show rapid desensiti-
zation in response to all agonists described. Thus, such compounds
do not represent direct replacements for the sustained activation
and resulting physiological depression of ivermectin. This does
not, however, rule out the future identiﬁcation of related
compounds that bind to the agonist binding site and show less
desensitization. Furthermore, compounds binding at this site could
be effective by other mechanisms. By binding to the equivalent site
to agonists but at a different subunit interface, they may enhance
agonist-induced currents, like benzodiazepines at GABAARs (Sigel
and Buhr, 1997). Conversely, structurally analogous compounds
could foreseeably act as competitive antagonists, as is the case at
iGluRs (Du et al., 2012). Such drugs could inhibit GluCl signaling
and cause hyperexcitability, similar to the common insecticides
that block GABAAR ion channels (Bloomquist, 1996). Admittedly,
C. elegans is reasonably tolerant of GluCl mutations (Dent et al.,
2000), suggesting that GluCl antagonists could constitute less
effective nematicides than GluCl agonists.4.2. Modulators in the GluCl TMD
Given the recent demonstration that propofol inhibits the AVR-
14B GluCl (Lynagh and Laube, 2014), it is perhaps not surprising
that it also inhibits the SmGluCl-2. The potency was, however,
some 4-fold lower at the SmGluCl-2. Based on our docking of
propofol to homology models, this difference may be due to an
M3 isoleucine residue in the SmGluCl-2 that prevents propofol
from accessing exactly the same site as in the AVR-14B (site 1,
between M3 and M1 helices of adjacent subunits), and restricts
the propofol molecule to site 2 (between adjacent subunits but
closer to M2 helices). This is in strict accord with mutagenesis data,
where an M3 glycine-isoleucine mutation reduces propofol
sensitivity of the AVR-14B GluCl (Lynagh and Laube, 2014).
Thymol, which differs from propofol in that the 6-isopropyl
group is replaced by a 5-methyl group, inhibited the SmGluCl-2
with higher potency than propofol but inhibited the AVR-14B with
lower potency than propofol. In our dockings to the SmGluCl-2
model, the poses of propofol and thymol were generally similar,
occupying in most cases site 2 (with the exception of the highly-
ranked pose of thymol in close proximity to M3 in site 1;
Fig. 6E). The major difference between the ligands appears to be
the orientation of the ligand hydroxyl, which in most poses ori-
ented towards M1 for the more potent ligand, thymol, such that
it can form an H-bond with a backbone carbonyl made available
by the conserved M1 proline (Hibbs and Gouaux, 2011). Similarly,
in the AVR-14B model, the phenyl ring of both ligands occupies site
1, but the hydroxyl is oriented towards the same M1 backbone car-
bonyl speciﬁcally in the case of propofol, the more potent inhibitor
of AVR-14B. Hydrogen-bonding to the backbone carbonyl of this
GluCl M1 position has also been demonstrated for ivermectin
(Hibbs and Gouaux, 2011), although the latter occupies a much
larger volume, makes numerous other interactions and enhanceschannel gating (Hibbs and Gouaux, 2011). Our dockings suggest
no reason for the lower potency of the non-phenyl ligand menthol,
as its location and orientation in both models appears nearly iden-
tical to thymol. We are also at a loss to explain the small enhance-
ment by thymol of the sustained current at AVR-14B (section 3.3,
above). However, whether monoterpenoid binding inclines the
agonist-bound channel towards a closed or open state is quite sus-
ceptible to structural alterations in the TMD (Lynagh and Laube,
2014); it is easy to imagine that thymol binding to structurally dis-
tinct resting, open or desensitized AVR-14B channels could exert
opposing effects, manifest in inhibition of peak currents but small
enhancement of sustained/desensitized currents.
Given the effects on monoterpenoid sensitivity of mutations
(Lynagh and Laube, 2014) or naturally occurring differences
(present study) at the GluCl M3 position, together with the fact
that all compounds docked to either site 1 or 2 between adjacent
subunits (and not once to a possible site within individual
subunits), we conclude that the intersubunit cavity of the GluCl
TMD is the most likely binding site for monoterpenoids. It should
be noted that this cavity may be artiﬁcially enlarged in our models
due to the presence of bound ivermectin in the template GLC-1
structure. (Each of the four available GLC-1 crystal structures
include ivermectin (Hibbs and Gouaux, 2011); we have utilized
the one complexed with L-glutamate.) Nevertheless, inspection of
the GLC-1 structure and residue conservation within GluCls
suggest that there is unlikely to be a plausible intrasubunit cavity
that can bind monoterpenoids, as exists in cation-selective pLGICs
(Nury et al., 2011). Both intersubunit sites 1 and 2 are also in close
proximity to the M2 150 residue, a determinant of propofol sensi-
tivity in GABAARs and GlyRs (Pistis et al., 1999; Siegwart et al.,
2003; Ahrens et al., 2008), and the M2 170 residue that binds
ortho-propofol diazirine in GABAARs (Yip et al., 2013). In fact, one
isopropyl group of propofol is oriented directly towards the M2
170 serine residue in SmGluCl-2 (position 4 in Fig. 6I) that equates
to the M2 histidine residue in GABAARs that binds the diazirine of
ortho-propofol diazirine (Yip et al., 2013).
Propofol is widely used for its anesthetic effects, which are
likely mediated via its enhancement of GABAARs and GlyRs
(Franks and Lieb, 1994; Nguyen et al., 2009). Thymol is a naturally
occurring compound that also enhances GABAARs, both of the
heteromeric human and homomeric Drosophila melanogaster
isoforms (Priestley et al., 2003). We think monoterpenoids hold
promise for the development of potent GluCl modulators for the
following reasons. Firstly, chemical ﬁne-tuning of potency and
selectivity of such compounds has already been demonstrated.
For example, halogenation of the C4 position of propofol leads to
remarkable increases in potency at mammalian a1 GlyRs (de la
Roche et al., 2012), has little effect on potency at mammalian
a1b1c2 GABAARs (Trapani et al., 1998), and decreases potency at
mammalian a1b2c2 GABAARs (Krasowski et al., 2001). Secondly,
binding sites between subunits occur in both roundworm and
ﬂatworm GluCls. This is remarkable when compared to ivermectin,
whose inactivity at ﬂatworms is due to molecular differences at
this very site (Lynagh and Lynch, 2012a; Dufour et al., 2013). It is
doubtful that this particular site could be targeted by a single drug
of a broad helminth spectrum, however, as differential potency at
roundworm vs. ﬂatworm GluCls seems common to these modula-
tors. Finally, numerous monoterpenoids, with similar structures
and properties to the compounds examined here, occur naturally.
Thus, nature provides a large number of compounds that could
be tested for potent modulation of GluCls. On this note, it is
intriguing that several such compounds (including thymol and
menthol), or the plants from which they derive, are toxic to
H. contortus (Carvalho et al., 2012; Boubaker Elandalousi et al.,
2013; Zhu et al., 2013), although it is pure speculation that this
toxicity could involve GluCls.
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This study reveals that a ﬂatworm and a roundworm GluCl
harbor binding sites in the extracellular domain for agonists
related to L-glutamate but of notable differences in size and
functional groups. Furthermore, it shows that both of these GluCls
also harbor a transmembrane cavity to which monoterpenoids
bind and inhibit channel activation by L-glutamate. Each agonist
or modulator examined was of relatively low potency – high
micromolar and low millimolar concentrations are required
for efﬁcient channel modulation or activation, respectively –
rendering them unsuitable for anthelmintic use. However, we
propose that subtly divergent compounds could exert similar
effects but with much greater potency and thus provide
leads for the development of much-needed drugs against
schistosomiasis. Furthermore, as the extracellular site shows
signiﬁcant pharmacological similarity between ﬂatworm and
roundworm GluCls, drugs targeting this site could constitute
anthelmintics of a very broad spectrum.
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